Sharon Bio-Medicine Ltd
Sharon Bio-Medicine Limited is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and commercialization of pharmaceutical products. The Company operates in three segments, which include Active Pharma Ingredients (API's), Formulations and Toxicology.
- Market Cap ₹ 39.2 Cr.
- Current Price ₹ 3.30
- High / Low ₹ /
- Stock P/E 2.06
- Book Value ₹ -49.6
- Dividend Yield 0.00 %
- ROCE 8.36 %
- ROE %
- Face Value ₹ 2.00
Pros
- Company's working capital requirements have reduced from 48.8 days to 30.8 days
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
420 | 496 | 606 | 785 | 1,060 | 1,314 | 834 | 253 | 171 | 173 | 188 | 195 | |
381 | 445 | 535 | 690 | 939 | 1,157 | 868 | 387 | 145 | 151 | 162 | 170 | |
Operating Profit | 39 | 52 | 71 | 95 | 120 | 157 | -34 | -134 | 26 | 22 | 26 | 25 |
OPM % | 9% | 10% | 12% | 12% | 11% | 12% | -4% | -53% | 15% | 13% | 14% | 13% |
2 | -0 | 1 | 1 | 1 | 2 | -74 | -69 | -72 | 4 | 3 | 4 | |
Interest | 14 | 21 | 27 | 34 | 43 | 59 | 94 | 71 | 0 | 0 | 0 | 0 |
Depreciation | 4 | 6 | 8 | 9 | 12 | 15 | 19 | 15 | 11 | 12 | 11 | 11 |
Profit before tax | 22 | 24 | 36 | 53 | 66 | 85 | -221 | -289 | -56 | 14 | 18 | 19 |
Tax % | 16% | 22% | 15% | 22% | 20% | 18% | 2% | 3% | 0% | 0% | 0% | 0% |
19 | 19 | 31 | 42 | 53 | 70 | -226 | -299 | -56 | 14 | 18 | 19 | |
EPS in Rs | 1.76 | 1.77 | 2.95 | 3.94 | 5.01 | 6.59 | -18.99 | -25.16 | -4.75 | 1.18 | 1.49 | 1.60 |
Dividend Payout % | 7% | 8% | 6% | 5% | 3% | 5% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -13% |
5 Years: | % |
3 Years: | 4% |
TTM: | 4% |
Compounded Profit Growth | |
---|---|
10 Years: | -8% |
5 Years: | % |
3 Years: | 4% |
TTM: | 8% |
Stock Price CAGR | |
---|---|
10 Years: | -27% |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11 | 11 | 11 | 11 | 11 | 21 | 24 | 24 | 24 | 1 | 1 | 1 |
Reserves | 96 | 112 | 188 | 182 | 179 | 242 | 81 | -219 | -664 | -627 | -610 | -592 |
262 | 343 | 344 | 508 | 644 | 725 | 824 | 836 | 828 | 828 | 828 | 828 | |
29 | 35 | 44 | 74 | 139 | 173 | 83 | 82 | 88 | 88 | 80 | 76 | |
Total Liabilities | 397 | 501 | 586 | 774 | 972 | 1,162 | 1,012 | 723 | 276 | 290 | 299 | 313 |
56 | 184 | 181 | 201 | 272 | 325 | 332 | 319 | 149 | 141 | 135 | 128 | |
CWIP | 107 | 23 | 27 | 60 | 43 | 15 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 1 | 4 | 4 | 4 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
233 | 290 | 374 | 509 | 654 | 820 | 678 | 404 | 128 | 149 | 164 | 185 | |
Total Assets | 397 | 501 | 586 | 774 | 972 | 1,162 | 1,012 | 723 | 276 | 290 | 299 | 313 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-50 | -28 | -36 | -53 | -70 | -69 | -82 | -28 | 35 | 4 | 23 | 41 | |
-66 | -51 | -8 | -61 | -64 | -27 | -10 | 0 | -7 | -4 | -3 | -3 | |
47 | 78 | 46 | 117 | 134 | 103 | 96 | 22 | 0 | 0 | 0 | 0 | |
Net Cash Flow | -69 | -1 | 1 | 2 | -0 | 6 | 4 | -6 | 28 | 0 | 20 | 38 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 116 | 117 | 116 | 121 | 122 | 115 | 138 | 264 | 47 | 62 | 52 | 49 |
Inventory Days | 90 | 102 | 112 | 109 | 105 | 106 | 136 | 198 | 173 | 209 | 162 | 149 |
Days Payable | 23 | 23 | 23 | 28 | 24 | 20 | 23 | 44 | 214 | 183 | 167 | 155 |
Cash Conversion Cycle | 183 | 195 | 205 | 202 | 203 | 201 | 251 | 418 | 7 | 88 | 48 | 43 |
Working Capital Days | 176 | 188 | 200 | 203 | 197 | 200 | 261 | 490 | 9 | 56 | 60 | 31 |
ROCE % | 11% | 11% | 13% | 14% | 14% | 16% | -5% | -18% | 7% | 8% | 8% |
Documents
Announcements
- Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP) 30 Jun 2023
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Jun 2023 - Copies of Newspaper advertisement published on June 1, 2023 given in Free Press Journal and Navshakti on the Audited Financial Results of the Company for …
- Compliances-Reg.24(A)-Annual Secretarial Compliance 30 May 2023
- Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31St , 2023 30 May 2023
- Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31St , 2023 30 May 2023